Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.

A series of stories that looks at the breakthroughs, setbacks, and overall status of vaccines and cures for hard-to-treat ...

Market SizeThe global genome editing market was valued at USD 5.5 billion in 2022 and is projected to grow at a CAGR of 13.9% ...

Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the ...

A research group led by Jacob Corn has just discovered that the use of AZD7648 has serious side effects. The study has just ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), with a price ...

MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the ...

Researchers expand the CRISPR genome engineering toolbox with transposase-assisted target-site integration (TATSI), a ...

Thanks to the revolutionary advancements in CRISPR technology, medical specialists are on the verge of transforming how we ...

Scientists in Asia and Africa are racing to discover hardier crop varieties using gene editing tools. But patent restrictions ...

Researchers have uncovered a serious side effect of using the CRISPR-Cas gene scissors. A molecule designed to make the process more efficient destroys parts of the genome.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a Nobel Prize-winning gene-editing tool, already widely ...